RxDoctor Payments DataLook up a doctor →

John Rodgers, MD

Pulmonary Disease · Glastonbury, CTNPI 1588641112

Payments from drug & device makers

$18,362in general payments, 2019–2025

Across 1,039 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$5K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$792
  • Mallinckrodt Hospital Products Inc.$671
  • plus $8K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK298$4,765
AstraZeneca99$2,028
Boehringer Ingelheim74$1,419
Novo Nordisk58$1,092
Lilly USA, LLC45$792
Mallinckrodt Hospital Products Inc.43$671
Takeda Pharmaceuticals U.S.A., Inc.43$656
AbbVie(2 entities)45$639
Sanofi24$612
Genentech USA, Inc.32$518
Johnson & Johnson(3 entities)29$517
Amgen(2 entities)26$485
Pfizer20$373
Novartis18$361
Regeneron Healthcare Solutions, Inc.15$287
Actelion Pharmaceuticals US, Inc.13$248
Merck14$224
Abbott11$209
Eisai Inc.11$189
Verona Pharma, Inc.7$158
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$151
Amarin Pharma, Inc.8$137
Grifols USA, LLC6$131
Exact Sciences4$119
E.r. Squibb & Sons, L.L.C.6$115
Mylan Specialty L.p.6$113
Mallinckrodt Enterprises LLC9$110
Kowa Pharmaceuticals America, Inc.8$110
Advanced Respiratory, Inc5$94
Viatris Specialty LLC4$92
Sunovion Pharmaceuticals Inc.6$82
Bausch Health US, LLC4$75
Shire North American Group Inc3$60
Amneal Pharmaceuticals LLC3$54
Philips North America LLC3$52
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$50
Bayer2$46
Vanda Pharmaceuticals Inc.1$40
Insmed, Inc.2$38
Arbor Pharmaceuticals, Inc.2$38
Biohaven Pharmaceutical Holding Company Ltd.2$36
Inspire Medical Systems, Inc.1$33
Teleflex LLC1$33
Astellas Pharma US Inc2$29
Covis Pharma GmbH1$26
CSL Behring1$25
Valencia Technologies Corporation1$24
Linus Health, Inc.1$23
Scilex Pharmaceuticals Inc.1$23
Medtronic1$20
Gilead1$20
Idorsia Pharmaceuticals US Inc1$19
USWM, LLC1$18
Optinose US, Inc.1$17
Sanofi-aventis U.S. LLC1$15
Hikma Pharmaceuticals USA1$15
Nabriva Therapeutics, PLC1$12
Assertio Therapeutics, Inc.1$12
Circassia Inc.1$12

How this compares

$18,362 in reported general payments places this provider in the 85th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut →

Medicare billing

Part B allowed, 2024
$106,187
Medicare patients
220
Services billed
1,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Glastonbury

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →